"10.1371_journal.pone.0132430","plos one","2015-07-24T00:00:00Z","Steven F L van Lelyveld; Julia Drylewicz; Maaike Krikke; Ellen M Veel; Sigrid A Otto; Clemens Richter; Robin Soetekouw; Jan M Prins; Kees Brinkman; Jan Willem Mulder; Frank Kroon; Ananja Middel; Jori Symons; Annemarie M J Wensing; Monique Nijhuis; Jos√© A M Borghans; Kiki Tesselaar; Andy I M Hoepelman; MIRS study group","Department of Internal Medicine & Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Immunology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands; Department of Internal Medicine & Gastroenterology, Spaarne Gasthuis, Haarlem, The Netherlands; Department of Internal Medicine, Division of Infectious Diseases, Center for Infection and Immunity, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands; Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands","Conceived and designed the experiments: SFLL MK SAO MN KT AIMH. Performed the experiments: SFLL EMV SAO JS. Analyzed the data: SFLL JD MK JAMB MN AMJW AM JS KT AIMH. Contributed reagents/materials/analysis tools: SFLL JD SAO CR RS JMP KB JWM FK JS AMJW MN JAMB KT. Wrote the paper: SFLL JD MK EMV CR RS JMP KB JWM FK AM JAMB AMJW MN KT AIMH. Designed and executed the MIRS study: MIRS study group investigators.","I have read the journals policy and the authors of this manuscript have the following competing interests: S.F.L.L. has received financial support for research, travel, speaking engagements or consultancy from BMS, GSK, Janssen-Cilag, Pfizer, Roche and ViiV healthcare; C.R. received financial support for consultancy or speaking engagements from BMS, Janssen-Cilag, Janssen EMEA and MSD. JMP has received financial support for travel from Pfizer. K.B. received financial support for consultancy from BMS, Gilead, Janssen-Cilag, MSD and ViiV healthcare. A.I.M.H. has received grant support from Pfizer. For the remaining authors none competing interests were declared. This disclosure does not alter our adherence to PLOS ONE policies on sharing data and materials.","2015","07","Steven F L van Lelyveld","SFLVL",19,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
